
Browsing restrictions can be lifted for a fee.
Apex Medical Corp. provides medical solutions for healthcare professionals worldwide. The company offers wound management products, including Serene Air and Serene Elite, which are alternating pressure redistribution systems for patients with high to very high risk for pressure ulcers; ACS Turn, a lateral turning mattress for prevention of ventilator-associated pneumonia; Pro-care Optima, an alternating pressure redistribution system for patients with high to very high risk of pressure injuries; Pro-care turn, a bilateral turning air mattress for patients with medium to high risk of pressure injuries; Domus Auto, Domus 4, and Verso for patients with medium to high risk of pressure injury; Domus 3 for patients with medium risk of pressure injury; Domus 2s for patients with low to medium risk of pressure injury; Domus 1 for patients in low risk of pressure injury; Sedens 500 and Sedens 400, which are seat cushions; and Flexi-Air, a non-powered hybrid mattress. It also provides respiratory therapy products, such as nasal masks, full face masks, nasal pillows mask, portable suction unit, and compressor nebulizers; iCH Auto and XT Auto for automatic positive airway pressure; XT Prime, XT Sense, and XT Fit for continuous positive airway pressure; and medical equipment. Apex Medical Corp. was founded in 1990 and is headquartered in New Taipei City, Taiwan.
4106
雃博
0.00%
(0.00)
The most recent financial report for 雃博 (4106) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4106's short-term business performance and financial health. For the latest updates on 4106's earnings releases, visit this page regularly.
According to historical valuation range analysis, 雃博 (4106)'s current price-to-earnings (P/E) ratio is 11.97, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 雃博 (4106) reported an Operating Profit of 55.68M with an Operating Margin of 8.99% this period, representing a growth of 2,971.04% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 雃博 (4106) announced revenue of 619.09M, with a Year-Over-Year growth rate of 14.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 雃博 (4106) held Total Cash and Cash Equivalents of 681.2M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 雃博 (4106) achieved the “three margins increasing” benchmark, with a gross margin of 46.71%%, operating margin of 8.99%%, and net margin of 7.66%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4106's profit trajectory and future growth potential.
According to the past four quarterly reports, 雃博 (4106)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.46. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
雃博 (4106)'s Free Cash Flow (FCF) for the period is -30.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 334.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.